SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as traders speculate about upcoming Phase 3 HOPE-3 data for DMD, which is expected to be a major catalyst. Community members are discussing potential leaks, short squeezes, and the impact of the data on the company's future, with some expressing concerns about short positions. Many believe positive results could send the stock soaring, while others remain cautious.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crypto, crow with knife ($CAW), is gaining attention, with the community highlighting its multichain functionality and burn mechanisms. There's enthusiasm around the project's organic growth and strong community, often referred to as the 'caWmunity'. Bullish sentiment is expressed with 'caw caw' and references to potential gains within the Solana ecosystem.

Bondex is a web 3.0 professional network where users own part of the ecosystem earn rewards and monetise their network.

Bondex

Bondex ($BDXN) is trending with significant volume and price movement, especially after a recent token unlock event that the market absorbed well. The community is actively discussing its strong performance relative to other tokens and the potential for further gains, highlighting positive technical indicators. Bondex's focus on Web3 talent networking and recent acquisitions are also fueling interest.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide is trending as investors discuss its potential following a surge in robotaxi revenue and increased institutional interest, including recent share purchases by ARK Invest and a Buy rating from Bank of America. Community members are highlighting the company's global expansion, particularly the launch of fully driverless robotaxi services in Abu Dhabi through Uber. Discussions also involve comparing WeRide's technology and market strategy with competitors like Pony.ai, and anticipating further catalysts by year-end.

American Eagle Outfitters, Inc. is a multi-brand specialty retailer, which offers an assortment of apparel and accessories for men and women under the American Eagle Outfitters brand, and intimates, apparel and personal care products for women under the Aerie brand. The firm operates stores in the United States, Canada, Mexico, Hong Kong, China and the United Kingdom. It also acquired two emerging brands to complement its existing brands, Tailgate, a vintage sports-inspired apparel brand, and Todd Snyder New York, a premium menswear brand. The company was founded in 1977 and is headquartered in Pittsburgh, PA.

American Eagle Outfitters Inc.

American Eagle Outfitters, Inc.

American Eagle Outfitters is trending after reporting a Q3 earnings beat, driven by strong comparable sales growth and successful marketing campaigns featuring celebrities like Sydney Sweeney. The community is focused on the company's raised Q4 operating income guidance and potential for continued growth during the holiday season. Some traders are wary of the stock being overbought, while others believe it has strong momentum and could reach new highs.

Gitlab, Inc. provides code hosting and collaboration platform services. It offers continuous integration, source code management, out-of-the-box pipelines, agile development, and value stream management. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in Dover, DE.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

GitLab is trending amidst discussions of a potential acquisition by Datadog, reportedly at a price over $60 per share, though neither company has confirmed the takeover.  The community is weighing the potential deal, with some analysts expressing skepticism, and debating whether GitLab is undervalued, with some suggesting the stock should be worth significantly more. Despite the unconfirmed rumors, GitLab's strong revenue growth and AI integration remain key points of discussion.

Sailana Inu, the sister of legendary Saitama Inu, is bringing back the Wolfpack and OG community vibes that previously sent Saitama to a $7 billion marketcap in 2021. The power of community mixed with great leadership is what will take this project to great heights. Join the movement, join the pack, become apart of the Sailana Army . Together, we will create something that will go down in history, and something that will be talked about years from now.

Sailana Inu

Sailana Inu is trending as its community, the Wolfpack, expresses strong conviction and dedication to the project. Discussions highlight the community's active role in building and shilling the coin, with some drawing comparisons to early Shiba Inu. The upcoming WolfSWAP, supporting over 20 chains, is also generating excitement.

Asana, Inc. engages in the business of developing a work management platform that helps organizations orchestrate work from daily tasks to cross-functional strategic initiatives. The company was founded by Dustin Moskovitz and Justin Michael Rosenstein on December 16, 2008 and is headquartered in San Francisco, CA.

Asana Inc - Ordinary Shares - Class A

Asana Inc

Asana's stock is trending due to positive earnings and guidance, with the company achieving cash flow positivity, which is a key talking point among investors. Community members are focused on the potential for a breakout, fueled by bullish options activity and the belief that the market has not yet priced in the company's improved financials. Broader discussions include the company's certifications for global compliance and its unique FedRAMP authorization.

FTI Consulting, Inc. engages in the provision of financial, legal, operational, political and regulatory, reputational and transactional advisory services. It operates through the following segments: Corporate Finance and Restructuring, Forensic and Litigation Consulting, Economic Consulting, Technology, and Strategic Communications. The Corporate Finance and Restructuring segment focus on the strategic, operational, financial, and capital needs of clients. The Forensic and Litigation Consulting segment offers law firms, companies, government clients, and other interested parties with multidisciplinary, independent dispute advisory, investigations, data analytics, forensic accounting, business intelligence, risk mitigation services and interim management services for health solutions practice clients. The Economic Consulting segment consists of the analysis of complex economic issues for use in legal, regulatory and international arbitration proceedings, strategic decision making, and public policy debates for law firms, companies, government entities and other interested parties. The Technology segment includes a portfolio of information governance, e-discovery and data analytics software, services, and consulting support to corporations, law firms, courts and government agencies. The Strategic Communications segment designs and executes communications strategies for management teams and boards of directors relating to managing financial, regulatory and reputational challenges, navigating market disruptions, articulating brand, staking a competitive position, and preserving and growing operations. The company was founded by Dan Luczak and Joseph Reynolds in 1982 and is headquartered in Washington, DC.

FTI Consulting Inc.

FTI Consulting ($FCN) is trending due to community discussion around potential connections to LumiraDx's ($LMDX) collapse and the emergence of ElectraDx, with concerns raised about asset diversion and insider enrichment. Option activity is also contributing to the buzz, as traders highlight significant ROI from call options on the stock. Overall, the community is scrutinizing FCN's role in the LumiraDx situation.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai ($AI) is trending amid mixed sentiment, with some traders highlighting its potential for a short squeeze given its high short interest and others pointing to upcoming earnings as a potential catalyst. Bullish investors are discussing the company's Microsoft partnership and potential for AI to take off in 2026, while bearish investors are expressing concerns about its financial performance and leadership.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

CPRX or DSNKY: Which Is the Better Value Stock Right Now?

CPRX vs. DSNKY: Which Stock Is the Better Value Option?

Wall Street Analysts Think Catalyst (CPRX) Could Surge 47.37%: Read This Before Placing a Bet

The mean of analysts' price targets for Catalyst (CPRX) points to a 47.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?

Here is how ADC Therapeutics SA (ADCT) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.

Skandinaviska Enskilda Banken AB publ Trims Stake in Catalyst Pharmaceuticals, Inc. $CPRX

Skandinaviska Enskilda Banken AB publ lessened its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 29.8% in the 2nd quarter, according to its most recent Form 13F...

Carmen Jeffrey Del Sells 10,983 Shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) insider Carmen Jeffrey Del sold 10,983 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, November 26th. The shares...

Catalyst Pharmaceuticals (NASDAQ:CPRX) Insider Sells $256,233.39 in Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) insider Carmen Jeffrey Del sold 10,983 shares of the business's stock in a transaction on Wednesday, November 26th. The shares were sold...

Zacks Research Issues Pessimistic Estimate for CPRX Earnings

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) - Research analysts at Zacks Research lowered their Q4 2025 earnings per share (EPS) estimates for Catalyst Pharmaceuticals in a research...

Summit Global Investments Reduces Stake in Catalyst Pharmaceuticals, Inc. $CPRX

Summit Global Investments lessened its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 19.4% in the 2nd quarter, according to the company in its most recent Form...

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

CPRX
Catalyst Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CPRX News

CPRXCatalyst Pharmaceuticals Inc